Resmetirom, a thyroid hormone receptor beta (THR-β) agonist, was recently approved by the United States Food and Drug Administration (FDA) for MASH treatment, but only for patients with F2/F3 fibrosis [35]. The gene discussed is THRB; the disease is fibrosis.